CD4 and myeloid sarcoma: All MS patients, including POMS, are characterized by an early immunosenescence since disease onset, with shorter telomerase, thymic dysfunction, increased CD4+/CD28- T Lymphocytes and memory T cells levels, reduced number of naïve T cells, and less functional regulatory T cells (9).